Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Evangelia Kranias
University of Cincinnati, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
NanoCor Therapeutics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Please see attached document.
Cardiac Sarcoplasmic Reticulum Calcium Cycling Proteins
Heart disease remains the leading cause of death and disability in the western world. Current therapy aims at treating the symptoms rather than the etiology of heart failure development. A universal characteristic of failing hearts is impaired calcium cycling through the sarcoplasmic reticulum, reflecting depressed pumping action of the heart. We have identified a novel regulator of sarcoplasmic reticulum activity and cell death, the small heat shock protein 20 (Hsp20). Here we will focus on understanding the function of this regulator in depth under the physiological stress of aging and the pathological stress, following myocardial infarction. Furthermore, we will elucidate the significance of a human mutation in Hsp20, as it appears to alter cardiac function and survival. These studies will provide the basis to develop new therapy targeting Hsp20 with the potential to increase both contractility and cell survival in heart disease.
Filed on February 03, 2014.
Tell us what you know about Evangelia Kranias's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Evangelia Kranias filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Evangelia Kranias | University of Cincinnati | Conflict of Interest | NanoCor Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.